The International Council of Biotechnology Associations (ICBA) is a coalition of non-profit, national biotechnology trade associations formed to promote public understanding of, and to advocate for, public policies that support the growth of the innovative biotechnology industries. The ICBA represents the global voice of the industry in international fora with the goal of promoting continued innovation in the human health, agriculture, and industrial and environmental sectors.
Steve Bates (Chair, ICBA)
CEO, UK BioIndustry Association
Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, antimicrobial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society’s Science, Industry and Translation Committee.
Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.
Oliver Schacht (Vice-Chair, ICBA)
CEO and President, OpGen, Inc.
Mr. Oliver Schacht, a corporate finance professional and expert in the molecular diagnostics industry, is the CEO of OpGen has been CEO of Curetis since April 2011 and prior to that was a Supervisory Board Member of Curetis AG from mid-2010 to end of the first quarter in 2011. He was a co-founder and CFO of Epigenomics AG (Berlin, Germany) and the CEO of Epigenomics Inc. (Seattle, USA). Mr. Schacht has extensive experience in developing and implementing commercial strategies and financing measures (including two IPOs), as well as corporate finance, investor relations, PR, marketing and business development. Mr. Schacht also serves on the Board of ICBA as its Vice Chairman and BIO Deutschland e.V. as its president and previously as treasurer.
Mr. Schacht obtained his Diploma in European Business Administration at the European School of Business in Reutlingen and London in 1994 as well as a Master’s degree and a Ph.D. at the University of Cambridge (UK). During his time at Mercer Management Consulting (now Oliver Wyman) from 1995 to 1999, he worked on projects in M&A, growth strategies and re-organization in the pharmaceutical, biotechnology and other industries.
He has co-founded several start-up companies in biotech, clean tech, IT and education in Europe and the USA.
Program Director, International Council of Biotechnology Associations
Senior Manager, International Affairs, Biotechnology Innovation Organization
As Senior Manager for International Affairs at the Biotechnology Innovation Organization (BIO), Ms. Stiss is responsible for managing the industry association’s program of international advocacy and outreach for Europe, the Middle East, North Africa, Turkey and South Africa regions. In this position, she engages with foreign officials in these regions to promote policies that support a strong biotechnology industry as well as to resolve policy issues relevant to the industry. Hilary also works on issues at the multilateral organizations as well as acts as program director for the International Council on Biotechnology Associations (ICBA).
Before taking this position at BIO, Hilary was a Graduate Fellow in the Scientific and Regulatory Affairs Department at the trade association, Pharmaceutical Research and Manufacturers of America (PhRMA). Prior to this appointment, Hilary received her Master’s degree from the Fletcher School of Law and Diplomacy, where she studied international political economy and international trade. During her studies, Hilary worked as a research associate in Amgen’s Washington, DC office.
Hilary completed her undergraduate degree cum laude with honors from Colgate University in 2009, where she studied conflict resolution and history.
International Council of
1201 New York Avenue NW
Washington, DC 20024